1-[2-(2-Fluoro-4-methylphenoxy)ethyl]piperidine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-[2-(2-Fluoro-4-methylphenoxy)ethyl]piperidine
• 英文别名: 1-[2-(2-fluoro-4-methylphenoxy)ethyl]piperidine
• 化学式: C₁₄H₂₀FNO
• 分子量: 237.31
• InChiKey: SAACBRCXXZKFDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• COMPOUND INHIBITING ACTIVITIES OF BTK AND/OR JAK3 KINASES
  申请人：BEIJING HANMI PHARMACEUTICAL CO., LTD.

  公开号：US20160229865A1

  公开（公告）日：2016-08-11

  The present invention relates to a compound inhibiting the activities of Bruton's tyrosine kinase (BTK) and/or Janus kinase 3 (JAK3), a pharmaceutical composition of the compound, pharmaceutical applications of same, a method for using the compound in inhibiting the activities of BTK and/or JAK3, and a method for using the compound in treatment and/or prevention of BTK- and/or JAK3-mediated diseases or disorders in mammals (especially human). The compound is as represented by structural formula (I).

  本发明涉及一种抑制布鲁顿酪氨酸激酶（BTK）和/或Janus激酶3（JAK3）活性的化合物，该化合物的制药组合物，其制药应用，使用该化合物抑制BTK和/或JAK3活性的方法以及使用该化合物治疗和/或预防哺乳动物（尤其是人类）中BTK和/或JAK3介导的疾病或疾病的方法。该化合物的结构式（I）如下：
• Compounds and methods for CDK8 modulation and indications therefor
  申请人：Plexxikon Inc.

  公开号：US10703757B2

  公开（公告）日：2020-07-07

  Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R4, X3, X4, X5, X6, X7 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.

  公开了式 I 的化合物： 或其药学上可接受的盐、溶解物、同分异构体、异构体或氚代类似物，其中 R4、X3、X4、X5、X6、X7 和环 A 如本公开所述的任一实施方案中所述；其组合物；及其用途。
• COMPOUNDS AND METHODS FOR CDK8 MODULATION AND INDICATIONS THEREFOR
  申请人：Plexxikon Inc.

  公开号：US20180215763A1

  公开（公告）日：2018-08-02

  Disclosed are compounds of Formula I: or a pharmaceutically acceptable salt, a solvate, a tautomer, an isomer or a deuterated analog thereof, wherein R 4 , X 3 , X 4 , X 5 , X 6 , X 7 and Ring A are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.
• US9840517B2
  申请人：——

  公开号：US9840517B2

  公开（公告）日：2017-12-12